LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Inicio・Lista de Acciones・Amgen Inc

Amgen Inc

Cerrado

Sector Salud

321.39 -0.06

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

320.33

Máximo

324.88

Métricas clave
By Trading Economics
Ingresos	859M 746M
Ventas	940M 8.4B
P/B Media del Sector	44.64 112.16
BPA	4.97
Margen de beneficio	8.892
Empleados	26,700
EBITDA	847M 3B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+5.99 upside

Dividendos
By Dow Jones
Próximas Ganancias	30 oct 2024
Fecha Próximo Dividendo	6 dic 2024
Próxima Fecha de Ex Dividendo	14 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	4.1B 175B
Apertura anterior	321.45
Cierre anterior	321.39

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

148 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

319.73 / 322.41 Soporte y Resistencia

Amgen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 ago 2024, 21:00 UTC

Ganancias

Amgen 2Q Revenue Jumps, Profit Narrows on Higher Expenses

2 may 2024, 20:42 UTC

Ganancias

Amgen Posts Higher 1Q Revenue, Swings to Loss

25 sept 2024, 16:19 UTC

Principales Noticias

Dow Falls, Nasdaq Rises, Chinese Shares Rally -- WSJ

20 sept 2024, 13:55 UTC

Principales Noticias

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

10 sept 2024, 20:38 UTC

Adquisiciones, fusiones, absorciones

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

10 sept 2024, 14:42 UTC

Adquisiciones, fusiones, absorciones

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

7 ago 2024, 14:22 UTC

Principales Noticias

Ganancias

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 ago 2024, 09:07 UTC

Ganancias

Acciones populares

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 ago 2024, 08:55 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

6 ago 2024, 20:20 UTC

Ganancias

Amgen Sees FY24 Share Repurchases Not Exceeding $500 M >AMGN

6 ago 2024, 20:20 UTC

Ganancias

Amgen Sees FY24 Capital Expenditures About $1.3 B >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q EPS $1.38 >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Adj EPS $4.97 >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Worldwide Neulasta Sales $105M >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Worldwide Prolia Sales $1.17B >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen Sees FY Adj EPS $19.10-Adj EPS $20.10 >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Net $746M >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Worldwide XGEVA Sales $562M >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen Sees FY EPS $6.57-EPS $7.62 >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Rev $8.4B >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen 2Q Worldwide Enbrel Sales $909M >AMGN

6 ago 2024, 20:01 UTC

Ganancias

Amgen Sees FY Rev $32.8B-$33.8B >AMGN

6 ago 2024, 08:45 UTC

Principales Noticias

Ganancias

These Stocks Are Moving the Most Today: Palantir, Nvidia, Apple, Lumen, Lucid, Caterpillar, and More -- Barrons.com

19 jul 2024, 11:00 UTC

Principales Noticias

Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ

19 jun 2024, 05:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

3 may 2024, 14:43 UTC

Acciones populares

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3 may 2024, 11:43 UTC

Charlas de Mercado

Ganancias

Amgen's Weight-Loss Drug Prospects Win New Bull -- Market Talk

3 may 2024, 08:45 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Apple, Amgen, Block -- WSJ

3 may 2024, 08:28 UTC

Ganancias

These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Amgen Inc Esperado

Precio Objetivo

By TipRanks

5.99% repunte

Estimación a 12 meses

Media 340.89 USD 5.99%

Máximo 405 USD

Mínimo 215 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

22 ratings

Comprar

Mantener

Vender

De acuerdo con 22 analistas que ofrecen calificaciones bursátiles a para Amgen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

319.73 / 322.41Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimiento

By Acuity

148 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.